At the news
? BULLISHIMPACT 7/10 6-K filed Jul 14, 2026 at 06:37 ET
AstraZeneca signed an exclusive global license agreement for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for non-small cell lung cancer with exon 20 insertion mutations. AstraZeneca pays Dizal Pharmaceutical an upfront $600 million plus up to $900 million in milestones, plus tiered royalties, adding a complementary approved asset to its lung cancer portfolio with positive Phase III data already filed for first-line use.
- AstraZeneca licensed worldwide rights to Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor for NSCLC with EGFR exon 20 insertion mutations.
- Upfront payment of $600 million to Dizal, with up to $900 million in development, regulatory, and sales milestones, plus tiered royalties on global sales.
- Zegfrovy is already approved in the US and China for second-line treatment after platinum-based chemotherapy.
- Positive WU-KONG28 Phase III data presented at ASCO 2026 and published in NEJM; sNDA for first-line use submitted to FDA and CDE.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access